Related Experiment Video
Updated: Oct 3, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
Haemodynamic effects of midazolam in the anaesthetized patient with coronary artery disease
Abstract:
The haemodynamic effects of midazolam 0.25 mg/kg administered intravenously were studied in eight anaesthetized patients suffering from coronary artery disease. Heart rate, systemic and pulmonary pressures, right atrial pressure, capillary pressure and cardiac output were measured 2, 5, 8 and 12 min after injection of midazolam and were compared with reference values collected before the commencement of the haemodynamic test. The cardiovascular condition of all the patients followed the same course after the injection of midazolam. The greatest variations were seen at the twelfth minute, with the exception of capillary pressure where the largest decrease was noted at the eighth minute. These variations, expressed as a percentage of the initial values, were: mean arterial pressure -17% (P less than 0.01); capillary pressure -23.5% (eight minute, P less than 0.01); heart rate - 9% (P less than 0.01); cardiac index -9% (P less than 0.01); systemic vascular resistance -12% (eighth minute, P less than 0.01). The stroke volume was well maintained (+0.1% NS). These haemodynamic variations were accompanied by a favourable evolution of the endocardial viability ratio (EVR), +12% (P less than 0.01). The slight tachycardia occasionally seen on induction of anaesthesia with midazolam was not seen in this group of patients. We conclude that these haemodynamic variations leading to an increase in EVR support the use of midazolam as a supplement to fentanyl anaesthesia for patients with coronary artery disease.
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Parenteral Anesthetics: Overview

